ACADIA CFO exercises options, sells 20,141 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.
He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F4 | 14,292 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,292 | $17.84 | $255K |
| Sale | Common Stock F2 | 5,000 | $29.00 | $145K |
| Sale | Common Stock F2 | 9,292 | $29.3375 | $273K |
| Exercise | Stock Option (Right to Buy) F4 | 5,849 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 5,849 | $17.84 | $104K |
| Sale | Common Stock F2, F3 | 5,849 | $29.0029 | $170K |
Footnotes (4)
- F1. Includes 1,683 shares of the Issuer's common stock acquired by the reporting person on May 15, 2026 pursuant to an employee stock purchase plan.
- F2. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 19, 2025.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4. 25% of the shares subject to the Stock Option vested and became exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
Key Figures
Key Terms
Rule 10b5-1 Plan regulatory
weighted average price financial
employee stock purchase plan financial
vest and become exercisable financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ACAD (ACADIA Pharmaceuticals) CFO Mark Schneyer report?
Were the ACAD CFO’s stock sales executed under a Rule 10b5-1 plan?
What was the exercise price of the ACADIA CFO’s stock options?
How do the ACAD CFO’s option vesting terms relate to these exercises?
AI-generated analysis. How Rhea-AI works. Not financial advice.